Owners, management and financials
CVR: 31853923
Previous names: STENO DIABETES CENTER A/S
DKK -64,000
Gross profit
Net result: DKK -23,000
NOVO NORDISK A/S (100%)
CVR · view owners
Anders Rytter Mikkelsen
Board: Naja Eilers Barrisøe (chair) and 2 members
CVR · view management
Active
Founded 17 November 2008
CVR · view overview
0 employees
CVR · 2017
Director role ended: Peter Bøggild
CVR · 12/05/2026
View the full event history
Novo Nordisk Invest 4 A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2008. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named STENO DIABETES CENTER A/S. The management consists of Anders Rytter Mikkelsen. The board consists of Naja Eilers Barrisøe (chair), Linette Tangsgaard Nielsen and Thomas Rask Nielsen. The company is owned by NOVO NORDISK A/S. The company has 0 employees (2017). In 2025, the company reported a gross profit of DKK -64,000 and a net result of DKK -23,000 compared with DKK 7,000 the year before. Equity in the 2025 report amounted to DKK 1,772,000.
Selskabets formål er at besidde ejerandele i selskaber i ind- og udland, at foretage investerings- og finansieringsvirksomhed, herunder anbringelse af kapital i virksomheder og fast ejendom i ind- og udland samt efter bestyrelsens nærmere bestemmelse at servicere sådanne selskaber og virksomheder driftsmæssigt.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | - | -23K | 1.8M | 1.8M | 0 | |
| 202401/01/2024 – 31/12/2024 | - | 7K | 1.8M | 1.8M | - | |
| 202301/01/2023 – 31/12/2023 | - | 5K | 1.8M | 1.8M | - | |
| 202201/01/2022 – 31/12/2022 | - | 4K | 2M | 1.8M | - | |
| 202101/01/2021 – 31/12/2021 | - | -37K | 2.2M | 1.8M | - | |
| 202001/01/2020 – 31/12/2020 | - | -108K | 2.3M | 1.8M | - | |
| 201901/01/2019 – 31/12/2019 | - | -398K | 9.2M | 8.9M | - | |
| 201801/01/2018 – 31/12/2018 | - | 189K | 10.2M | 9.3M | - | |
| 201701/01/2017 – 31/12/2017 | - | -775K | 11.6M | 9.1M | - | |
| 201601/01/2016 – 31/12/2016 | - | -407K | 85.5M | 9.9M | - | |
| 201501/01/2015 – 31/12/2015 | 219.3M | 803K | 86.7M | 10.3M | - | |
| 201301/01/2013 – 31/12/2013 | 181.8M | -214K | 66.8M | 5.7M | - |
Compared to 50.000 companies in Ikke-finansielle holdingselskaber
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationThe CVR number of Novo Nordisk Invest 4 A/S is 31853923.
Novo Nordisk Invest 4 A/S is owned by NOVO NORDISK A/S.
The management of Novo Nordisk Invest 4 A/S consists of Anders Rytter Mikkelsen.
The board of Novo Nordisk Invest 4 A/S consists of Naja Eilers Barrisøe, Linette Tangsgaard Nielsen and Thomas Rask Nielsen, with Naja Eilers Barrisøe as chair.
In 2025, Novo Nordisk Invest 4 A/S reported a gross profit of DKK -64,000.
Novo Nordisk Invest 4 A/S had 0 employees in 2017 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Contact info changed: new phone: 44448888 (October 9, 2026).
As of October 8, 2026, Thomas Rask Nielsen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of October 8, 2026, John Francis Kuckelman has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2025. Gross profit came to DKK -64,000, and the net result was DKK -23,000.
Contact info changed: new phone: 44448888 (May 13, 2026).
As of May 12, 2026, Anders Rytter Mikkelsen is registered as director of Novo Nordisk Invest 4 A/S.
As of May 12, 2026, Peter Bøggild has stepped down as director of Novo Nordisk Invest 4 A/S.
As of December 8, 2025, Naja Eilers Barrisøe has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of December 8, 2025, Karsten Munk Knudsen has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2024. Gross profit came to DKK -55,000, and the net result was DKK 7,000.
Novo Nordisk Invest 4 A/S has published its annual report for 2023. Gross profit came to DKK -53,000, and the net result was DKK 5,000.
As of May 23, 2024, John Francis Kuckelman has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of May 23, 2024, Kristine Aachmann Bethe has left the board of directors of Novo Nordisk Invest 4 A/S.
As of June 30, 2023, Kristine Aachmann Bethe has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of June 30, 2023, Tomas Haagen has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2022. Gross profit came to DKK -6,000, and the net result was DKK 4,000.
Novo Nordisk Invest 4 A/S has published its annual report for 2021. The net result was DKK -37,000.
Novo Nordisk Invest 4 A/S has published its annual report for 2020. The net result was DKK -108,000.
As of May 12, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Novo Nordisk Invest 4 A/S.
As of May 12, 2021, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Novo Nordisk Invest 4 A/S.
As of December 15, 2020, Linette Tangsgaard Nielsen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of December 15, 2020, Lene Moth Bang has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2019. The net result was DKK -398,000.
Novo Nordisk Invest 4 A/S has published its annual report for 2018. The net result was DKK 189,000.
As of October 1, 2018, Tomas Haagen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of October 1, 2018, Ole Falvig Ramsby has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2017. The net result was DKK -775,000.
As of April 25, 2018, Karsten Munk Knudsen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of April 25, 2018, Jesper Brandgaard has left the board of directors of Novo Nordisk Invest 4 A/S.
As of April 25, 2018, Peter Bøggild is registered as director of Novo Nordisk Invest 4 A/S.
As of April 25, 2018, Karsten Munk Knudsen has stepped down as director of Novo Nordisk Invest 4 A/S.
As of June 1, 2017, Lene Moth Bang has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of June 1, 2017, Lars Fruergaard Jørgensen has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2016. The net result was DKK -407,000.
As of January 1, 2017, Ole Falvig Ramsby has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Jesper Brandgaard has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Lars Fruergaard Jørgensen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Anne Birgitte Urup Hemmingsen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Birgitte Nauntofte has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Kirsten Engelhard Nielsen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Mads Krogsgaard Thomsen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Søren Thor Jensen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Nana Folmann Hempler has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Majken Borup Linnemann Jensen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Kristine Færch has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Alan Charles Moses has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Bo Ahrén has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Karsten Munk Knudsen is registered as director of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, John James Nolan has stepped down as director of Novo Nordisk Invest 4 A/S.
On January 1, 2017, the company changed its name from STENO DIABETES CENTER A/S to Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2015. Revenue came to DKK 219,295,000, and the net result was DKK 803,000.
Novo Nordisk Invest 4 A/S has published its annual report for 2014.
As of December 9, 2014, Peter Jens Lindholm Kurtzhals has left the board of directors of Novo Nordisk Invest 4 A/S.
As of November 27, 2014, Mads Krogsgaard Thomsen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of November 27, 2014, Lars Rebien Sørensen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of November 25, 2014, Lars Rebien Sørensen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of November 25, 2014, Lise Kingo has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2013. Revenue came to DKK 181,767,000, and the net result was DKK -214,000.
Novo Nordisk Invest 4 A/S has published its annual report for 2012.
As of March 22, 2013, Nana Folmann Hempler has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Majken Borup Linnemann Jensen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Kristine Færch has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Bo Ahrén has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Dorthe Tecza has left the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Peder Rasmussen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2013, Niels Borregaard has left the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2012, Søren Thor Jensen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 22, 2012, Ole Falvig Ramsby has left the board of directors of Novo Nordisk Invest 4 A/S.
As of November 10, 2011, Alan Charles Moses has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of July 1, 2011, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Novo Nordisk Invest 4 A/S.
As of July 1, 2011, A/S PSE NR. 4820 has stepped down as auditor of Novo Nordisk Invest 4 A/S.
As of March 15, 2011, Birgitte Nauntofte has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of March 15, 2011, Martinus Hermanus Soeters has left the board of directors of Novo Nordisk Invest 4 A/S.
As of February 10, 2011, Dorthe Tecza has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of February 10, 2011, Allan Arthur Vaag has left the board of directors of Novo Nordisk Invest 4 A/S.
As of February 10, 2011, Dorthe Tecza has left the board of directors of Novo Nordisk Invest 4 A/S.
As of February 10, 2011, Charlotte Brøns has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2011, John James Nolan is registered as director of Novo Nordisk Invest 4 A/S.
As of January 1, 2011, Knut Borch-Johnsen has stepped down as director of Novo Nordisk Invest 4 A/S.
As of November 3, 2009, Gert Almind Frederiksen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of April 22, 2009, Allan Arthur Vaag has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of April 22, 2009, Anne Birgitte Urup Hemmingsen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of April 22, 2009, Dorthe Tecza has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of April 22, 2009, Peder Rasmussen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of April 22, 2009, Charlotte Brøns has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of April 22, 2009, Kirsten Engelhard Nielsen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 16, 2009, Gert Almind Frederiksen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 16, 2009, Niels Borregaard has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 16, 2009, Lise Kingo has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 16, 2009, Peter Jens Lindholm Kurtzhals has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 16, 2009, Martinus Hermanus Soeters has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 16, 2009, Lars Rebien Sørensen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of November 17, 2008, A/S PSE NR. 4820 has been appointed auditor of Novo Nordisk Invest 4 A/S.
As of November 17, 2008, Ole Falvig Ramsby has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of November 17, 2008, Lars Rebien Sørensen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of November 17, 2008, Knut Borch-Johnsen is registered as director of Novo Nordisk Invest 4 A/S.
As of November 17, 2008, NOVO NORDISK A/S is registered as an owner of Novo Nordisk Invest 4 A/S with an ownership share of 100%.
Novo Nordisk Invest 4 A/S was founded on November 17, 2008.
Companies in the same industry and area
CVR 40121846
CVR 37868957
CVR 33392982
CVR 39866471
CVR 45897125
